Anti-CD20 monoclonal antibodies, including rituximab, obinutuzumab, and ublituximab, have shown significant efficacy when combined with venetoclax in treating CLL. This evidence concerns the gene MS4A1 and B-cell chronic lymphocytic leukemia.